MedTrace Logo

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

NCT05901584 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-18

No results posted yet for this study

Summary

This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer

Conditions

  • Immunotherapy
  • Second-line Treatment

Interventions

DRUG

Cadonilimab

Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.

Sponsors & Collaborators

  • Guizhou Provincial People's Hospital

    collaborator OTHER

  • The First People's Hospital of Zunyi

    collaborator OTHER

  • Guizhou Tongren People's Hospital

    collaborator UNKNOWN

  • The People"s Hospital of Xingyi

    collaborator UNKNOWN

  • The Second Affiliated Hospital of Guizhou Medical University

    collaborator UNKNOWN

  • Second Affiliated Hospital of Zunyi Medical University

    lead OTHER

Principal Investigators

  • Hu Ma, Ph.D · The Second Affiliated Hospital of Zunyi Medical University

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05901584 on ClinicalTrials.gov